Condition (MeSH)
Carcinogenesis
ClinicalTrials.gov lists 381 trials for Carcinogenesis or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 42.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
2 more sections with rows
26 of the 381 trials are tagged with Carcinogenesis itself; the rest are tagged with a narrower condition beneath it.
When did Carcinogenesis trials start? (36)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Expanded access, Unknown)
Top of scale: 30
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 3 |
| 2021 | 2 |
| 2020 | 7 |
| 2019 | 1 |
| 2018 | 10 |
| 2017 | 4 |
Showing 10 of 36 earlier years.
No forecast is made for this condition: it averages 2.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 43 months across 300 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Carcinogenesis trials in? (10)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 108 |
| Phase 1/2 | 42 |
| Phase 2 | 115 |
| Phase 2/3 | 2 |
| Phase 3 | 25 |
| Phase 4 | 3 |
| Not applicable | 39 |
| Observational | 43 |
| Expanded access | 3 |
| Unknown | 1 |
How many Carcinogenesis trials are recruiting? (9)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 16 |
| Active, not recruiting | 11 |
| Completed | 258 |
| Approved for marketing | 1 |
Showing 5 of 9 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Carcinogenesis trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 42 |
| Novartis Pharmaceuticals | 6 |
Which drugs are being tested for Carcinogenesis? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 64 |
| Busulfan | 43 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SQ Fludarabine | 61 |
| Peripheral blood stem cell transplantation | 58 |
| IR Tacrolimus | 39 |
| HD- Methotrexate (MTX) | 38 |
| Allogeneic (Allo) hematopoietic stem cell transplantation | 37 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Carcinogenesis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Death | 217 | 9 |
| 1 yr TRM | 93 | 1 |
| Febrile neutropenia | 65 | 11 |
| Infections and infestations - Other | 50 | 2 |
| Mucositis oral | 48 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Carcinogenesis? (231)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Pyruvate metabolism enzyme DLAT promotes tumorigenesis by suppressing leucine catabolism. | Cell metabolism | 2025 | Yes |
| Mutagenesis and Carcinogenesis Risk Evaluation for AAV and Lentiviral Gene Therapies. | International journal of toxicology | 2025 | Yes |
| Helicobacter pylori, microbiota and gastric cancer - principles of microorganism-driven carcinogenesis. | Nature reviews. Gastroenterology & hepatology | 2025 | Yes |
| Probiotics ameliorate H. pylori-associated gastric β-catenin and COX-2 carcinogenesis signaling by regulating miR-185. | Journal of biomedical science | 2025 | Yes |
| Cholecystectomy-related gut microbiota dysbiosis exacerbates colorectal tumorigenesis. | Nature communications | 2025 | Yes |
Showing 5 of 231 publications.
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.